Support Resources

hrwcaresico-triesence

Harrow Cares helps you use TRIESENCE with confidence

Enroll via Fax, online at HarrowCares.com, or find our enrollment form on PX Technology. Put the focus back on your patients.

A one-stop personalized support service for you,
your office staff, and your patients
Easy Enrollment

Streamlined enrollment for benefit investigation and product coverage information

Real-time updates on the progress of your patients’ support

Assistance for you and your patients from our dedicated call center in less than 30 seconds
Receive personalized access and cost support through a Harrow Cares specialist
Harrow Cares Commercial Copay Program

  • Available to commercially insured patients, excludes patients enrolled in Medicaid, Medicare, Tricare, etc.
  • Pay as little as $0
  • Program Maximum Annual Benefit: $5,000
  • Program Enrollment Period: Start Date through December 31 of that calendar year
  • Once enrolled, a claim should be sent to the program within 180 days of the date of treatment
  • If a patient was treated within the last 120 days, the program can look back and approve copay assistance. Enroll immediately using the Enrollment Form and attaching an EOB from the insurer

Harrow Cares, so we give prescribers and patients an easy,
fast, and simple solution to accessing therapy

*Subject to program terms and limitations. Please contact  1-866-HROWINC (476-9462)  for additional details.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE:

TRIESENCE® Suspension is indicated for:

  • Treatment of the following ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
  • Visualization during vitrectomy.
Contraindications
  • TRIESENCE® Suspension is contraindicated in patients with systemic fungal infections.
  • TRIESENCE® Suspension is also contraindicated in patients with hypersensitivity to corticosteroids or any component of TRIESENCE® Suspension. Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy.
Warnings and Precautions
  • TRIESENCE® is a suspension; it should not be administered intravenously.
  • Ophthalmic effects: May include cataracts, infections, and glaucoma. Monitor intraocular pressure.
  • Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome and hyperglycemia: Monitor patients for these conditions and taper doses gradually.
  • Infections: Increased susceptibility to new infection and increased risk of exacerbation, dissemination, or reactivation of latent infection.
  • Elevated blood pressure, salt and water retention, and hypokalemia: Monitor blood pressure and sodium, potassium serum levels.
  • GI perforation: Increased risk in patients with certain GI disorders.
  • Behavioral and mood disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis.
  • Decreases in bone density: Monitor bone density in patients receiving long term corticosteroid therapy.
  • Live or live attenuated vaccines: Do not administer to patients receiving immunosuppressive doses of corticosteroids.
  • Negative effects on growth and development: Monitor pediatric patients on long-term corticosteroid therapy.
  • Use in pregnancy: Fetal harm can occur with first trimester use.
  • Weight gain: May cause increased appetite.
Adverse Reactions
  • Based on a review of the available literature, the most commonly reported adverse events following ocular administration of triamcinolone acetonide were elevated intraocular pressure and cataract progression. These events have been reported to occur in 20-60% of patients.
  • Less common reactions occurring in up to 2% of patients include: endophthalmitis (infectious and non-infectious), hypopyon, injection site reactions (described as blurring and transient discomfort), glaucoma, vitreous floaters, detachment of retinal pigment epithelium, optic disc vascular disorder, eye inflammation, conjunctival hemorrhage and visual acuity reduced. Cases of exophthalmos have also been reported.
Drug Interactions
  • Anticoagulant Agents –Corticosteroids may enhance or diminish the anticoagulant effect of anticoagulant agents. Coagulation indices should be monitored.
  • Antidiabetic Agents –Corticosteroids may increase blood glucose concentrations. Dose adjustments of antidiabetic agents may be required.
  • CYP 3A4 Inducers and Inhibitors –CYP 3A4 inducers and inhibitors may respectively increase or decrease clearance of corticosteroids, necessitating dose adjustment.
  • NSAIDs –Concomitant use of NSAIDS, including aspirin and salicylates, with a corticosteroid may increase the risk of GI side effects.

For additional Important Safety Information about TRIESENCE® Suspension, please see the accompanying full Prescribing Information.